The role of Fc receptors and complement in autoimmunity

Autoimmunity Reviews

Volumn 12, Issue 6, 2013, Pages 657-660

  Mihai, Sidonia ^a   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoantibodies; Autoimmune diseases; Complement; FcRs

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 7; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2;

ANTIBODY RESPONSE; AUTOIMMUNITY; BULLOUS PEMPHIGOID; COMPLEMENT ACTIVATION; DISEASE MODEL; EPIDERMOLYSIS BULLOSA ACQUISITA; GOODPASTURE SYNDROME; IMMUNE RESPONSE; MEMBRANOUS GLOMERULONEPHRITIS; MONOCYTE; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; ARTHRITIS; AUTOIMMUNITY; BLISTER; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; RECEPTORS, FC;

EID: 84877074688     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.008     Document Type: Review

References (43)

1. Lux A., Aschermann S., Biburger M., Nimmerjahn F. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis 2010, 69(Suppl. 1):i92-i96.
2. Nimmerjahn F., Ravetch J.V. Antibody-mediated modulation of immune responses. Immunol Rev 2010, 236:265-275.
3. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008, 223:300-316.
4. Nandakumar K.S., Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 2006, 8:223.
5. Ji H., Ohmura K., Mahmood U., Lee D.M., Hofhuis F.M., Boackle S.A., et al. Arthritis critically dependent on innate immune system players. Immunity 2002, 16:157-168.
6. Nimmerjahn F., Lux A., Albert H., Woigk M., Lehmann C., Dudziak D., et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010, 107:19396-19401.
7. Kagari T., Tanaka D., Doi H., Shimozato T. Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol 2003, 170:4318-4324.
8. Banda N.K., Thurman J.M., Kraus D., Wood A., Carroll M.C., Arend W.P., et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 2006, 177:1904-1912.
9. Hietala M.A., Nandakumar K.S., Persson L., Fahlen S., Holmdahl R., Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004, 34:1208-1216.
10. Watson W.C., Brown P.S., Pitcock J.A., Townes A.S. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57Bl/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum 1987, 30:460-465.
11. Banda N.K., Hyatt S., Antonioli A.H., White J.T., Glogowska M., Takahashi K., et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 2012, 188:1469-1478.
12. Ballanti E., Perricone C., di Muzio G., Kroegler B., Chimenti M.S., Graceffa D., et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 2011, 10:617-623.
13. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture's disease. Lancet 2001, 358:917-920.
14. Sheerin N.S., Springall T., Abe K., Sacks S.H. Protection and injury: the differing roles of complement in the development of glomerular injury. Eur J Immunol 2001, 31:1255-1260.
15. Sheerin N.S., Springall T., Carroll M.C., Hartley B., Sacks S.H. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110:403-409.
16. Hebert M.J., Takano T., Papayianni A., Rennke H.G., Minto A., Salant D.J., et al. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 1998, 13:2799-2803.
17. Tarzi R.M., Cook H.T. Role of Fcgamma receptors in glomerulonephritis. Nephron Exp Nephrol 2003, 95:e7-e12.
18. Kaneko Y., Nimmerjahn F., Madaio M.P., Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006, 203:789-797.
19. Thurman J.M., Tchepeleva S.N., Haas M., Panzer S., Boackle S.A., Glogowska M.J., et al. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol 2012, 302:1529-1536.
20. Otten M.A., Groeneveld T.W., Flierman R., Rastaldi M.P., Trouw L.A., Faber-Krol M.C., et al. Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol 2009, 183:3980-3988.
21. Mihai S., Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007, 11:462-481.
22. Sitaru C., Mihai S., Otto C., Chiriac M.T., Hausser I., Dotterweich B., et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005, 115:870-878.
23. Woodley D.T., Chang C., Saadat P., Ram R., Liu Z., Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005, 124:958-964.
24. Sitaru C., Chiriac M.T., Mihai S., Buning J., Gebert A., Ishiko A., et al. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006, 177:3461-3468.
25. Chiriac M.T., Roesler J., Sindrilaru A., Scharffetter-Kochanek K., Zillikens D., Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007, 212:56-65.
26. Mihai S., Chiriac M.T., Takahashi K., Thurman J.M., Holers V.M., Zillikens D., et al. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178:6514-6521.
27. Kasperkiewicz M., Nimmerjahn F., Wende S., Hirose M., Iwata H., Jonkman M.F., et al. Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury. J Pathol 2012, 228:8-19.
28. Liu Z., Diaz L.A., Troy J.L., Taylor A.F., Emery D.J., Fairley J.A., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
29. Lessey E., Li N., Diaz L., Liu Z. Complement and cutaneous autoimmune blistering diseases. Immunol Res 2008, 41:223-232.
30. Zhao M., Trimbeger M.E., Li N., Diaz L.A., Shapiro S.D., Liu Z. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 2006, 177:3398-3405.
31. Ravetch J.V., Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998, 16:421-432.
32. Schmidt R.E., Gessner J.E. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005, 100:56-67.
33. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
34. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol 2009, 46:2753-2766.
35. Banda N.K., Levitt B., Wood A.K., Takahashi K., Stahl G.L., Holers V.M., et al. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol 2010, 159:100-108.
36. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002, 110:1823-1830.
37. Skokowa J., Ali S.R., Felda O., Kumar V., Konrad S., Shushakova N., et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005, 174:3041-3050.
38. Konrad S., Ali S.R., Wiege K., Syed S.N., Engling L., Piekorz R.P., et al. Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation. J Biol Chem 2008, 283:33296-33303.
39. Kumar V., Ali S.R., Konrad S., Zwirner J., Verbeek J.S., Schmidt R.E., et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006, 116:512-520.
40. Syed S.N., Konrad S., Wiege K., Nieswandt B., Nimmerjahn F., Schmidt R.E., et al. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a. Eur J Immunol 2009, 39:3343-3356.
41. Tsuboi N., Ernandez T., Li X., Nishi H., Cullere X., Mekala D., et al. Regulation of human neutrophil Fcgamma receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum 2011, 63:467-478.
42. Kelley J.M., Edberg J.C., Kimberly R.P. Pathways: strategies for susceptibility genes in SLE. Autoimmun Rev 2010, 9:473-476.
43. Sciascia S., Ceberio L., Garcia-Fernandez C., Roccatello D., Karim Y., Cuadrado M.J. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 2012, 12:157-163.